About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Long Covid
Cocaine Intoxication
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
COVID-19
Monkeypox
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-1300
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1800
Broad Spectrum Antivirals
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
IR Events
Investors
Investors
Overview
News & Events
Tonix in the News
Press Releases
IR Events
Email Alerts
Op-Eds
Presentations
Multimedia
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Virtual Q3 Investor Summit
Aug 16, 2022 9:30 am EDT
